A Food and Drug Administration (FDA) advisory panel on Friday significantly rejected the application of Jazz Pharmaceuticals for the approval of Xyrem (sodium oxybate) for the treatment of fibromyalgia.

The drug is chemically similar to GHB — the “date-rape” drug. Approving the drug for such a large patient population would risk flooding the streets with a [...]